Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hussein El-Newihi

Gastroenterology El Centro, CA Medical Doctor

NPI 1275580698 CMS profile 102783

1550 N Imperial Ave Ste 2, El Centro, CA 92243

Open in the dashboard

General payments

$5,721

236 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hussein El-Newihi of El Centro, CA is reported in the CMS Open Payments database as having received $5,721 across 236 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,227 42
2024 General $1,201 38
2023 General $805 38
2022 General $655 29
2021 General $614 29
2020 General $756 41
2019 General $463 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hussein El-Newihi
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Hussein El-Newihi were reported at $1,227. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Hussein El-Newihi Gastroenterology median Middle half National median
2019 $463 $417 $126–$1,100 $163
2020 $756 $224 $74–$624 $114
2021 $614 $352 $106–$1,054 $132
2022 $655 $448 $129–$1,270 $149
2023 $805 $533 $150–$1,390 $160
2024 $1,201 $605 $160–$1,606 $164
2025 $1,227 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $902 53 payments
  2. Regeneron Healthcare Solutions, Inc. $569 19 payments
  3. Ironwood Pharmaceuticals, Inc $516 25 payments
  4. AbbVie, Inc. $514 28 payments
  5. Madrigal Pharmaceuticals $425 16 payments
  6. Ipsen Biopharmaceuticals, Inc $325 12 payments
  7. Intercept Pharmaceuticals, Inc. $321 15 payments
  8. Phathom Pharmaceuticals, Inc. $260 2 payments
  9. Genzyme Corporation $222 4 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $199 9 payments
  11. Other $1,468 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,712 235 payments
  2. Education $9 1 payment
Products named General payments · program years 2019–2025
  1. TRULANCE $521 28 payments
  2. Linzess $516 25 payments
  3. IQIRVO $325 12 payments
  4. DUPIXENT Inflammation And Immunology $321 13 payments
  5. OCALIVA $285 13 payments
  6. REZDIFFRA $261 10 payments
  7. VOQUEZNA $260 2 payments
  8. DUPIXENT Immunology $222 4 payments
  9. ZEPOSIA $218 7 payments
  10. CREON $211 10 payments
  11. Other $2,876 133 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

4,624

Median for Gastroenterology: 569

Drug cost

$767,799

Median for Gastroenterology: $104,976

Branded share of claims

35.1%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ocaliva Obeticholic Acid Brand 31 $280,444
Linzess Linaclotide Brand 122 $95,344
Cimzia (2 Pack) Certolizumab Pegol Brand 13 $69,589
Creon Lipase/Protease/Amylase Brand 21 $52,352
Xifaxan Rifaximin Brand 12 $35,754
Trulance Plecanatide Brand 52 $34,700
Movantik Naloxegol Oxalate Brand 67 $34,347
Dexlansoprazole Dr Dexlansoprazole Brand 109 $33,986
Mesalamine Generic 36 $25,756
Ursodiol Generic 78 $12,743

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$270,849

Medicare's payments for the services billed

Medicare patients

1,432

Average age 74

Services billed

3,464

885 women, 547 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Diabetes 52%
Chronic kidney disease 41%
Ischemic heart disease 39%
Depression 31%
Osteoporosis 31%
Heart failure 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $260
$260 — —
RESMETIROM
  • Madrigal Pharmaceuticals $164
$164 — —
IQIRVO
  • Ipsen Biopharmaceuticals, Inc $158
$158 — —
Linzess
  • Ironwood Pharmaceuticals, Inc $157
$157 122 —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $143
$143 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

236 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record